Approxima Raises €7.3M Series A from ENEA Tech and Biomedical and Panakès Partners to Advance Tricuspid Valve Device into Clinical Trials
Approxima, a Milan-based MedTech startup developing a minimally invasive device for treating tricuspid valve regurgitation, has raised €7.3 million in Series A financing as it advances its cardiovascular intervention technology toward clinical validation and early human trials.
The company, founded in 2020 as a spin-off from Politecnico di Milano, is working on a percutaneous right ventricular remodeling system designed to restore proper tricuspid valve function by addressing ventricular dilation rather than only treating valve symptoms. Its approach targets patients with limited surgical options, offering a less invasive alternative to traditional open-heart procedures.
The Series A round was completed as a first closing and was co-led by ENEA Tech and Biomedical and Panakès Partners, with continued participation from existing investors including Club degli Investitori and several business angels. The funding round remains open to additional co-investors, reflecting continued interest from the broader MedTech investment community.
According to company disclosures, the capital raised will be directed toward advancing preclinical validation, initiating pilot clinical studies, and supporting an Early Feasibility Study in the United States. These steps are intended to demonstrate both safety and efficacy as the company prepares for regulatory milestones and potential commercialization pathways.
The involvement of ENEA Tech and Biomedical highlights growing institutional interest in MedTech innovation tied to structural heart disease, while Panakès Partners brings specialized healthcare venture expertise focused on medical device development. Their participation reflects a broader trend of European healthcare investors backing early-stage companies that aim to address unmet clinical needs through minimally invasive technologies.
Additional support from Club degli Investitori and angel investors underscores the hybrid structure of early-stage MedTech financing, where institutional venture capital is often combined with private angel syndicates to support capital-intensive clinical development cycles. This blended investor base is common in regulated healthcare innovation, where development timelines are longer and funding needs extend beyond typical software startup cycles.
Approxima’s technology focus on tricuspid regurgitation places it within a rapidly evolving segment of structural heart therapies, where innovation has historically lagged behind treatments for left-sided heart conditions. The company aims to fill this gap by offering a catheter-based solution that reshapes the right ventricle to improve valve performance and cardiac efficiency.
The startup’s leadership has emphasized that the funding will accelerate the transition from preclinical research to human trials, a critical inflection point for MedTech companies seeking regulatory approval and eventual market entry. The addition of new board members during the financing process also signals a strengthening governance structure as the company scales its clinical ambitions.
While Approxima’s funding round remains relatively modest compared to later-stage MedTech companies, it represents a significant step in de-risking its technology and building momentum toward larger institutional rounds typically required for commercialization and global expansion.
In the broader MedTech investment landscape, companies like Approxima often progress through staged financing cycles, beginning with seed and Series A rounds led by specialized healthcare investors before attracting larger growth equity or strategic corporate investors in later stages. For now, Approxima’s €7.3 million raise positions it to advance through the next critical phases of clinical development and regulatory validation.
